Medtronic has introduced a new type of remote glucose monitor that allows parents and caregivers to keep track of patients' blood sugar levels from a different room.
The new mySentry device has been approved by the US Food and Drug Administration and works in conjunction with the MiniMed Paradigm Real-Time Revel System.
It allows carers to track real-time insulin pump status and glucose trends, as well as hearing alerts and alarms, at their bedside, while diabetes sufferers remain in their own rooms.
This will help to minimise the number of severe hypoglycaemia incidents that typically take place during the night, providing peace of mind for caregivers while enhancing care quality for the patients themselves.
Greg Meehan, vice-president and general manager of the continuous glucose monitoring business at Medtronic, said it will "help people more proactively manage their diabetes by making it easier and more convenient to access the wealth of information captured by our integrated insulin pump and continuous glucose monitoring system".
Last month, the company published new data from a study showing the benefits its AdaptiveStim with RestoreSensor neurostimulation system can offer to chronic pain patients.